|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41.
Joensuu H et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Miller KD et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: A randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). Presentation. European Cancer Conference 2005a;Abstract 275.
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial conducted by the Eastern Cooperative Oncology Group (E2100). Presentation. San Antonio Breast Cancer Symposium 2005b;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005c;23(4):792-9. Abstract
Ordonez J et al. Trastuzumab in combination with bevacizumab in advanced breast cancer patients resistant to chemotherapy. Proc ASCO 2006;Abstract 10762.
O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1070.
O’Shaughnessy JA et al. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: A phase III trial. San Antonio Breast Cancer Symposium 2003;Abstract 44.
Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659- 72. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide
followed by docetaxel (AC 
T) with doxorubicin and cyclophosphamide followed
by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab
(TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio
Breast Cancer Symposium 2005;Abstract 1.
Thürlimann B et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract
 |
 |
